While tamoxifen has been the standard of therapy for ER/PR-positive breast cancers regardless of age for many years, recently the use of aromatase inhibitors and the addition of Ovarian Function Suppression (OFS) have been included in the treatment of young women [26]. Here, CYP19A1 is linked to breast cancer.